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Abstract
Background: In coeliac disease, ingestion of gluten induces the production of transglutaminase 2 (TG2)-targeted
autoantibodies by TG2-specific plasma cells present at high frequency in the small intestinal mucosa in untreated
disease. During treatment with a gluten-free diet (GFD), the number of these cells decreases considerably. It has not
been previously investigated whether the cells are also present prior to development of villous atrophy, or in non-
responsive patients and those with dietary lapses. We aimed to define the frequency of small bowel mucosal TG2-
specific plasma cells in coeliac disease patients with varying disease activity, and to investigate whether the frequency
correlates with serum and small intestinal TG2-targeting antibodies as well as mucosal morphology and the number of
intraepithelial lymphocytes.
Results: Mucosal TG2-specific plasma cells were found in 79% of patients prior to development of mucosal
damage, in all patients with villous atrophy, and in 63% of the patients after 1 year on GFD. In these disease
stages, TG2-specific plasma cells accounted for median of 2.3, 4.3, and 0.7% of all mucosal plasma cells, respectively.
After long-term treatment, the cells were present in 20% of the patients in clinical remission (median 0%) and in 60%
of the patients with poor dietary adherence (median 5.8%). In patients with non-responsive coeliac disease despite
strict GFD, the cells were found in only one (9%) subject; the cells accounted for 2.4% of all plasma cells. A positive
correlation between the percentage of TG2-specific plasma cells and serum TG2 antibody levels (rS = 0.69, P < 0.001)
and the intensity of mucosal TG2-targeting IgA deposits (rS = 0.43, P < 0.001) was observed.
Conclusions: Our results show that TG2-specific plasma cells are already detectable prior to villous atrophy, and that
generally their frequency increases during overt disease. By contrast, on GFD, the percentage of these cells decreases.
Overall, the presence of TG2-specific plasma cells in the small bowel mucosa mirrors the presence of gluten in the diet,
but the frequency is not always parallel to the level of serum or intestinal TG2 antibodies. These findings increase the
knowledge about the development of the TG2 plasma cell responses especially in the early phases of coeliac disease.
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Background
In coeliac disease, dietary gluten in wheat, rye, and
barley functions as a driving antigen for an abnormal
immune response that develops in genetically susceptible
individuals carrying the human leukocyte antigen
(HLA)-DQ2 or -DQ8 haplotypes. The disease is charac-
terised by small-bowel mucosal damage which develops
gradually from normal villous morphology to inflamma-
tion and finally to villous atrophy with crypt hyperplasia
diagnostic of coeliac disease. The intestinal damage is
often coupled with numerous gastrointestinal symptoms,
although various extraintestinal manifestations are also
prevalent. A specific characteristic of coeliac disease is
the generation of immunoglobulin class A (IgA)
antibodies towards the main autoantigen, transglutami-
nase 2 (TG2) [1]. These autoantibodies are generally
found in the circulation of coeliac disease patients [2]
and as deposits in the small intestinal mucosa below the
subepithelial basement membrane and around blood
vessels [3]. Interestingly, intestinal TG2-targeted
deposits can be detected even prior to manifest mucosal
damage and in the absence of serum antibodies [4–6].
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Upon removal of gluten from the diet, the only currently
available treatment, the clinical symptoms and histo-
pathological changes in the small intestine resolve, and
both the circulating and intestinal antibodies disappear
within 1 year in most patients [7]. However, a subset of
patients fails to respond to the dietary treatment and the
villous atrophy persists despite a strict gluten-free diet
(GFD). The most common reason for persistent villous
atrophy is either advertent or inadvertent gluten intake
or, in rare cases, refractory coeliac disease [8].
TG2-targeting antibodies were long thought to be
generated by intestinal plasma cells [9–11], but recent
data suggests that they might also be produced in
lymphoid tissues outside the gut [12]. In the small intes-
tine, the TG2-specific plasma cells are present at high
frequency during the active disease [10, 11], and they
decrease considerably within 6–12 months after com-
mencement of a strict GFD [11]. However, no data exist
regarding the presence of these cells in the early phases
of coeliac disease when the mucosal morphology is still
normal. In addition, their existence in non-responding
coeliac disease patients or those with dietary lapses has
not been previously investigated. With this in mind, we
enumerated the TG2-specific plasma cells in untreated
and treated coeliac patients with varying degrees of
disease activity, and investigated whether the number of
these cells correlates with serum TG2 antibody levels,
the intensity of mucosal TG2-targeting IgA deposits,
and small intestinal mucosal morphology and
inflammation.
Methods
Patients and study design
The study cohort comprised 46 coeliac disease patients
who underwent upper gastrointestinal endoscopy at the
Department of Gastroenterology and Alimentary Tract
Surgery of Tampere University Hospital (Table 1).
Fifteen of the patients were clinically suspected of having
coeliac disease based on gastrointestinal symptoms and
positive coeliac disease-specific autoantibodies (endomy-
sial and/or TG2 antibodies) despite having normal small
bowel mucosa (villous height crypt depth ratio (Vh/
CrD) ≥ 2). These patients were prospectively followed up
while they continued on a normal gluten-containing diet
Table 1 Demographic data and the small-bowel mucosal and serological findings of patients participating in the study
Prospectively studied coeliac patients
(n = 15)
Long-term treated coeliac patients
(n = 31)
Disease controls
(n = 25)
CD prior
to atrophy
n = 14
Overt CD
n = 15
1 year GFD
n = 11
Patients in
remission
n = 15
Non-
responding CD
n = 11
Patients with
dietary lapses
n = 5
Gluten
sensitivity
n = 18
Dyspepsia
n = 7
Female; n (%) 10 (71) 10 (67) 7 (64) 10 (67) 7 (64) 5 (100) 16 (89) 1 (14)
Age; median (range), years 55 (16–70) 55 (17–71) 57 (28–72) 59 (24–66) 49 (40–76) 51 (31–77) 49 (24–65) 47 (24–76)
Duration of GFD; median
(range), years
0 0 1 (1–1) 8 (3–34) 7 (3–24) 10 (9–17) 0 0
HLA-DQ2 or -DQ8-positive; n
(%)
14 (100) 15 (100) 11 (100) 15 (100) 11 (100) 4a (100) 9 (50) 1 (14)
EmA; median (range), titer 1:100 (0–
1:2000)
1:100 (0–
1:4000)
0 (0–1:50) 0 (0) 0 (0–1:5) 1:200 (0–
1:2000)
0 (0) 0 (0)
TG2 abs; median (range),
U/ml
9.4 (3.3- >
100)
11.9 (4.2- >
100)
3.9 (0–8.6) 0.5 (0–2.8) 1.3 (0–9.9) 56.9 (12.9- >
100)
1.4 (0–4.1) 0.6 (0–2.8)
Mucosal TG2-IgA deposits
present; n (%)
14 (100) 14a (100) 7b (88) 5 (33) 10a (100) 3c (100) 4 (22) 0 (100)
Vh/CrD; mean (95% CI), ratio 2.9 (2.6–3.1) 1.4 (1.1–1.7) 3.4 (2.4–4.5) 3.4 (3.2–
3.6)
0.2 (0.0–0.4) 0.5 (−0.3–1.3) 3.5 (3.0–
4.1)
3.5 (3.0–4.1)
CD3+ IELs; median
(range), cells/mm
54 (12–79) 67 (38–116) 39 (23–80) 42 (25–77) 60 (30–109) 50 (38–69) 21 (7–59) 26 (16–40)
αβ+ IELs; median
(range), cells/mm
30 (12–50) 43 (21–75) 22 (14–43) 31 (20–46) 44 (26–105) 38 (35–56) 16 (5–26) 22 (17–31)
γδ+ IELs; median
(range), cells/mm
18.8 (0–38.5) 23.7 (14–58.7) v13.6 (1.4–
56.3)
14.0 (7.3–
27.8)
12.1 (0–37.8) 13.0 (4.4–20.5) 2.7 (0–
10.2)
1.6 (0.7–
16.1)
abs antibodies, CD coeliac disease, CI confidence interval, EmA endomysial antibodies, GFD gluten-free diet, GS gluten sensitive; IgA immunoglobulin A; IELs
intraepithelial lymphocytes; TG2-abs, transglutaminase 2 antibodies; Vh/CrD villous height crypt depth ratio
Reference values set at 2.0 for Vh/CrD, 37 cells/mm for CD3+ IELs, 25 cells/mm for αβ+ IELs, and 4.3 cell/mm for γδ+ IELs (Järvinen et al., [15])
Cut-off value for TG2 antibodies ≥ 5 AU/ml
aData missing from one patient
bData missing from three patients
cData missing from two patients
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for 1 year, during which villous atrophy developed (Vh/
CrD < 2) in all patients. Thereafter, the patients started a
GFD, and after 1 year on the diet, their mucosal morph-
ology had recovered. Small bowel samples from 14 of
the patients at the time of the normal mucosal morph-
ology, all 15 patients at the time of the villous atrophy,
and 11 of the patients after 1 year on a GFD were avail-
able for the current study (Table 1).
Furthermore, 15 coeliac disease patients on a
long-term GFD without symptoms and evincing full
histological recovery, 11 non-responsive coeliac disease
patients with persistent villous atrophy despite a strict
GFD, and five patients with poor dietary adherence were
investigated. Twenty patients with self-reported gluten
sensitivity experiencing abdominal symptoms after con-
sumption of gluten-containing products [13] and seven
patients with dyspepsia served as the non-coeliac con-
trols in the study. All controls had been excluded for
coeliac disease, as demonstrated by negative serology
and normal small bowel mucosal morphology. The
demographic data and small-bowel mucosal and sero-
logical findings of all subjects are reported in Table 1.
The study protocol was approved by the Ethics
Committee of the Pirkanmaa Hospital District, Tampere,
Finland, and written informed consent was obtained
from all participating subjects.
Small-intestinal mucosal morphology and inflammation
Small-intestinal mucosal biopsies were obtained upon
upper gastrointestinal endoscopy. For morphological
studies, one formalin-fixed biopsy sample was stained
with haematoxylin and eosin to determine the villous
height-crypt depth ratios (Vh/CrD) according to a previ-
ously published procedure [14]. A ratio of ≥2 was con-
sidered normal. One of the biopsies was submerged in
optimal cutting temperature compound (OCT;
Tissue-Tek, Sakura Finetek Europe, Holland), followed
by snap-freezing in liquid nitrogen. Thereafter,
5-μm-thick sections were cut. According to an estab-
lished protocol [15], the sections were stained for CD3+,
αβ+, and γδ+ intraepithelial lymphocyte (IEL) subsets.
The reference values were 37 cells/mm, 25 cells/mm,
and 4.3 cells/mm for CD3+ IELs, γδ+ IELs and αβ+ IELs,
respectively [15].
Serological measurements and HLA genotyping
Serum endomysial antibodies (EmA) in IgA class were
determined by an indirect immunofluorescence method
exploiting human umbilical cord as substrate. A dilution
of 1:≥5 was considered positive [16]. Serum IgA-class
TG2 antibodies were measured by a commercially avail-
able enzyme-linked immunosorbent assay (Celikey®,
Phadia, Freiburg, Germany) in samples diluted 1:100. A
titre of ≥ 5 AU/ml was set as the cut-off for positivity.
SSP DQB1 low-resolution kit (Olerup SSP AB, Saltsjö-
baden, Sweden), DELFIA Celiac Disease Hybridization
Assay (PerkinElmer Life and Analytical Sciences, Wallac
Oy, Turku, Finland) or HLA-tagging single-nucleotide
peptides [17] were used for HLA genotyping.
Small-intestinal TG2-specific IgA deposits
For the determination of mucosal TG2-targeting IgA
deposits, frozen sections were stained with mouse
monoclonal anti-TG2 antibody (CUB7402; NeoMarkers,
Fremont, California, USA), followed by detection with
fluorescein isothiocyanate (FITC) -labelled rabbit
anti-human IgA antibody (Dako A/S, Glostrup,
Denmark) [3]. Based on their intensity along the base-
ment membrane in the villous-crypt area, the deposits
were graded blinded as a negative, or a weak, moderate,
or strong positive, as described previously [6].
Small-intestinal TG2-specific plasma cells
An earlier described technique was used to detect muco-
sal TG2-specific plasma cells [10]. Initially, 5-μm-thick
frozen sections were air-dried for 20 min at room
temperature (RT). After washing in PBS, the sections
were incubated with biotinylated human recombinant
TG2 (2 μg/ml; T002, Zedira) for 45 min at RT. Biotinyl-
ation was performed using EZ-Link®
Sulfo-NHS-LC-Biotin (Thermo Scientific, Waltham,
MA, USA) according to the instructions provided by the
manufacturer. Thereafter, the sections were incubated
with rhodamine-labelled streptavidin (1:1000; KPL,
Gaithersburg, MD, USA) for 30 min at RT. Plasma cells
were identified using a mouse monoclonal CD138 anti-
body (1:25; B-A38, Bio-Rad), followed by goat
anti-mouse IgG Alexa Fluor 488 (1:2000; A-11001,
Thermo-Fisher Scientific). Stainings were analysed at
20x and 40x magnification (Olympus BX60F5, Olympus
Optical Co. LTD, Japan) on two consecutive small intes-
tinal biopsy sections and the percentage of TG2-specific
cells out of all lamina propria plasma cells in the entire
section was determined.
Statistical analyses
Data are expressed as the number of subjects (n) and
percentages, or as medians and ranges. Statistical
analyses were performed using the Wilcoxon test or
Mann–Whitney test as appropriate. Correlation was
evaluated using Spearman’s correlation. Statistical testing
was performed using statistical analysis software (IBM
SPSS Statistics, SPSS Inc., Chicago, IL, USA). A P-value
< 0.05 was considered statistically significant.
Results
Of the 15 prospectively studied coeliac disease patients,
TG2-specific plasma cells were already present in 11 out
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of the 14 available small bowel samples (79%) from the
patients before the development of villous atrophy. The
median percentage of the cells was 2.3% (range 0–
12.7%) of all lamina propria plasma cells (Fig. 1a and b).
After continuing on a gluten-containing diet for 1 year
and developing overt small bowel mucosal damage, all
fifteen patients had intestinal TG2-specific plasma cells,
and the median percentage of the cells was 4.3% (range
1.8–8.8%) (P = 0.055 when compared to patients with
early-stage coeliac disease). By contrast, after 1 year on a
GFD, the cells were found in 7 out of 11 (64%) patients
with available samples, and the median percentage of
the cells significantly decreased to 0.7% (range 0–2.9%,
P = 0.003) when compared to the overt disease.
In long-term GFD-treated patients in clinical remis-
sion responding well to dietary treatment, only a few
remaining TG2-specific plasma cells (median 0.0%,
range 0–1.1%) were detected in 3 out of 15 (20%) of the
patients (Fig. 1a and b). In non-responding coeliac
disease patients on a strict GFD, the cells were mostly
absent, being present in only one patient (9%) who had
2.4% of TG2-specific cells out of all lamina propria
plasma cells. Of the coeliac disease patients with dietary
lapses, three out of five (60%) had TG2-specific plasma
cells, the median being 5.8% (range 0–7.0%). No
TG2-specific plasma cells were found in any of the
non-coeliac control patients with either gluten sensitivity
or dyspepsia.
A positive correlation between the percentage of
TG2-specific plasma cells and serum TG2 antibody
levels (rS = 0.690, P < 0.001, Fig. 2a) as well as EmA (rS =
0.712, P < 0.001) was observed when data from all
coeliac disease patient groups were included in the ana-
lysis. Similarly, the percentage of the TG2-specific
plasma cells correlated with the intensity of the small
intestinal IgA deposits in all coeliac disease patients (rS =
0.430, P < 0.001) (Fig. 2b). However, the percentage of
TG2-specific plasma cells did not correlate with serum
Fig. 1 a. The percentage of small-bowel mucosal transglutaminase 2 (TG2) -specific plasma cells out of all lamina propria plasma cells in the
different patient groups. b. Immunofluorescence staining for transglutaminase 2 (TG2) antibodies and plasma cells in small-bowel mucosal
sections. Representative picture of a coeliac disease patient prior to villous atrophy showing positive staining for TG2-specific plasma cells
(arrows). Recombinant TG2 (red), plasma cell marker CD138 (green), and their colocalisation (yellow) at 20x magnification. Scale bar = 100 μm.
Abbreviations: CD, coeliac disease; GFD, gluten-free diet
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or mucosal TG2 antibodies in any of the individual
coeliac disease patient groups (Additional file 1 Table
S1). Considering all coeliac disease patients, there was
no correlation between the percentage of the plasma
cells and Vh/CrD. Of the IELs, there was a modest cor-
relation between the percentage of TG2-specific plasma
cells and γδ+ IELs. Detailed information about the corre-
lations is presented in Additional file 1 Table S1.
Discussion
In the current study, we have discovered that
TG2-specific plasma cells are already present in most
patients prior to detectable mucosal damage. Moreover,
we showed that in the majority of cases the percentage
of these cells increases upon continuous gluten intake
and the subsequent development of villous atrophy. On
a strict GFD, the percentage of these cells declines. After
long-term treatment, the cells are mostly absent both in
patients in clinical remission and in non-responding
patients with persistent villous atrophy. By contrast,
TG2-specific plasma cells can be detected in patients
with dietary lapses. In controls, even those with
gluten-related symptoms, no cells were detected.
Our results from untreated and treated coeliac disease
patients are in line with previous studies [10, 11], show-
ing that the amount of TG2-specific plasma cells is ele-
vated in the small intestinal mucosa at the time of
diagnosis and this amount decreases on a GFD. It has
earlier been shown that the percentage of these cells out
of all lamina propria plasma cells accounts for up to
24% in overt disease, being on average 10% [10, 11].
However, in the current study, the corresponding per-
centages were lower. Our patients had been recruited to
the study while still having normal mucosal morphology,
and they developed overt villous atrophy within a
one-year follow-up on a gluten-containing diet. Thus, it
is conceivable that the patients had had flat mucosal
lesion for a reasonably shorter time than in the previous
a
b
Fig. 2 Correlation between the percentage of small intestinal transglutaminase 2 (TG2) -specific plasma cells and serum IgA class TG2 antibody
levels (a) and the intensity of small intestinal TG2-targeting immunoglobulin a (IgA) deposits (b) in all coeliac disease patients. Grading of IgA
deposits as follows: 0 = negative, 1 = weak, 2 = moderate, 3 = strong
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studies, which might explain the lower percentages of
TG2-specific plasma cells in our study.
TG2-specific plasma cells correlated positively with
serum TG2 antibody levels when the data of all coeliac
disease patients were analysed together. This correlation
most likely mirrors the responsiveness of the plasma cells
to gluten exposure which is not surprising in the light that
TG2 antibodies have been suggested to arise by a
hapten-carrier-like mechanism involving TG2-catalysed
generation of gluten-TG2 complexes [18, 19]. On the
other hand, correlations between the percentages of the
plasma cells and serum antibody levels were not detected
when different coeliac disease groups were analysed separ-
ately; this is in agreement with previous findings in
untreated coeliac disease patients [11]. It has been pro-
posed that the lack of correlation could be explained by
the production of the antibodies also outside the gut [11].
This concept has recently been further supported by the
finding that coeliac patient serum and intestinal TG2 anti-
bodies are clonally related but have different molecular
compositions, pointing to different sites of origin [12].
Such extraintestinal production of TG2 antibodies could
also explain why some patients in our study had serum
TG2 antibodies in the absence of intestinal TG2-specific
plasma cells.
Although small intestinal TG2-specific plasma cells
are not likely to be the major source of serum TG2 anti-
bodies [12], it would be logical to assume that the TG2
antibodies bound to their antigen in the small intestinal
mucosa and predicting forthcoming mucosal damage are
produced locally by lamina propria TG2-specific plasma
cells. In this study, we observed a correlation between
the percentage of the plasma cells and the intensity of
mucosal TG2-specific IgA deposits, which supports this
hypothesis. Interestingly, however, TG2-specific plasma
cells were mostly absent in non-responding coeliac
patients, even though they all presented with strong
TG2-targeting IgA deposits in the small intestinal
mucosa despite a strict GFD. It has been proposed that
the long persistence of small intestinal IgA deposits in
non-responsive patients on a strict diet may be
explained, for instance, by the high avidity binding of the
IgA antibodies to small intestinal TG2 [6, 7]. This
could explain the presence of IgA deposits in the
absence of TG2 antibody-secreting plasma cells in
our non-responsive patients. However, it does not
provide an explanation for the presence of IgA
deposits in the absence of plasma cells in the small
subset of patients prior to development of villous
atrophy. Similarly, it does not explain the presence of
weak IgA deposits without TG2-antibody secreting
plasma cells in a few gluten-sensitive control patients.
Whether extraintestinal production of TG2 antibodies
occurring for instance in the bone marrow, spleen
and lymph nodes contributes to the appearance of
mucosal IgA deposits remains to be addressed in
future studies.
Conclusions
We conclude that the TG2-specific plasma cells are
already present in the early phases of coeliac disease
when the mucosal morphology is still normal, their
percentage increases upon the development of villous
atrophy and decreases on a GFD. Overall, the frequency
of TG2 antibody-secreting plasma cells in the different
phases of coeliac disease reflects the presence of
gluten in the diet, but the frequency of these cells is
not always parallel with serum TG2 antibody levels or
the intensity of small intestinal TG2-targeting IgA
deposits. Our findings widen the understanding of
small-bowel mucosal TG2-specific plasma cells in
coeliac disease and thus provide further insight into
the generation of TG2 antibody responses.
Additional file
Additional file 1: Table S1. Correlations between the percentage of
TG2-specific plasma cells and other study parameters. (DOCX 15 kb)
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